



iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

Cancer Control in Europe: Finding Sustainable Solutions


13 - 14 December 2021



Co-funded by
the Health Programme
of the European Union

GENOMICS IN CANCER CONTROL AND CARE

Sciensano



Task 5.1: ELSI

Wannes Van Hoof (Belgium)

- **Task 5.2: Stratified genetic screening**
M. Zappa and P. Rossi (Italy)
- **Task 5.3: Implementing Genomics in the Healthcare system**
M. Van den Bulcke (Belgium)
- **Task 5.4 Direct-to-consumer testing**
S. Boccia and I. Hoxhaj (Italy)
- **Task 5.5: Education and training**
S. Boccia, I. Hoxha and R. De Angelis (Italy)

GENOMICS IN CANCER CONTROL AND CARE

Sciensano

- **The WP6 prepared in total 9 one-pagers:**

1. **DNA debat on use of genomic information: an IT platform**
2. The SIENNA approach on collecting citizen info from a large population
3. **Stratified genetic screening for high-risk breast cancer in Emilia Romagna: a real-life case**
4. Implementing NGS diagnostics in oncology in Belgium
5. Genome medicine in Italy
6. oncNGS Pre-commercial procurement: novel approach to sustainable complex oncologic diagnostics
7. **Direct-to-consumer testing: how to manage in a secure, open manner**
8. Education on genomics for health professionals, patients and citizens at large
9. e-Training of Health professionals and certification: an Italian initiative

Sciensano

3. POTENTIAL FOR FUTURE USE/VALUE OF OUTPUTS/LESSONS LEARNED

- Fostering **trust** is key in developing an ELSI framework for genomics – **vulnerability**
- Risk stratification should help maintain the right balance in screening: it is also important to look at the lower risk tail of the distribution
- Introduction of omics in routine diagnostics merits an implementation framework (e.g. roadbook type)
- Urgent need for training and education (online platforms) –clear curricula descriptions
- DTC is a point of attention

INNOVATIVE THERAPIES IN CANCER

French National Cancer Institute (INCa)

PARTICIPATING PARTNERS IN WP 9

		Tasks				
		9.1	9.2	9.3	9.4	9.5
Associated partners						
Belgium	Scientific Institute of Public Health (WIV-ISP)	X	X	X	X	X
Italie	CRO-Aviano (in collaboration with ISS)		X		X	X
Lituanie	National Centre of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos (VuHSK)		X	X		X
Serbia	Clinical Center of Kragujevac CCK (in collaboration with IPHS)	X		X	X	X
Slovaquie	Biomedical Research Center (BMC SAS)	X		X		X
Collaborative partners						
Spain	INCLIVA	X	X		X	X
	CIBERONC	X	X		X	X

French National Cancer Institute (INCa)

2. KEY OUTPUTS & OUTCOMES COMPLETED

1. Main results/outputs

- **Tasks 1 & 2:** two deliverables completed
 - **Innovative cancer therapies in clinical practice guidelines (July 2019)**
 - **Reference frameworks linked with the access to innovative immunotherapies (July 2019)**
- **Tasks 2 & 3:** one deliverable completed: **Horizon scanning systems applied for cancer control in Europe (Sept 2020)**
- **Task 4:** one deliverable : **Real life monitoring of immunotherapies focus on patients treated with CAR-T cells (June 2021).**

2. Dissemination of the WP 9 results/outputs

- Local stakeholder forum (december 2019), international/european congress (DIA, ASCO, WCPH in 2020)
- Final WP9 workshop to present results of the WP9 will be planned at the end of 2021

French National Cancer Institute (INCa)

3. POTENTIAL FOR FUTURE USE/VALUE OF OUTPUTS/LESSONS LEARNED

- Several examples of European initiatives and programs found interesting by partners, member state representatives and/or stakeholders in the field of clinical practice guidelines, access to innovative therapies, Horizon scanning systems and real-life monitoring of innovative cancer therapies have been presented in the roadmap.
- Some recommendations for further European collaborations have been suggested in the deliverables (ex: develop guidelines repository to better identify existing guidelines in Europe ; pooling experiences/sharing challenges encountered in HSS at the European level).

THANK YOU!